Cargando…

Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C

BACKGROUND/AIMS: Genetic variants of MHC class I polypeptide-related chain A (MICA) at rs2596542 have been associated with hepatocellular carcinoma. The linkage between serum MICA (sMICA) and liver fibrosis in chronic hepatitis C is elusive. RESULTS: Linear regression analysis revealed that sMICA we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Chung-Feng, Huang, Ching-I, Yeh, Ming-Lun, Wang, Shu-Chi, Chen, Kuan-Yu, Ko, Yu-Min, Lin, Ching-Chih, Tsai, Yi-Shan, Tsai, Pei-Chien, Lin, Zu-Yau, Chen, Shinn-Cherng, Dai, Chia-Yen, Huang, Jee-Fu, Chuang, Wan-Long, Yu, Ming-Lung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464814/ https://www.ncbi.nlm.nih.gov/pubmed/28427234 http://dx.doi.org/10.18632/oncotarget.15941

Ejemplares similares

Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Corrigendum to “Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment” [EBioMedicine 15 (2017) 81–89]
por: Huang, Chung-Feng, et al.
Publicado: (2017)

Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection
por: Huang, Chung-Feng, et al.
Publicado: (2018)

Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2016)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma
por: Yeh, Ming-Lun, et al.
Publicado: (2017)

Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals
por: Huang, Chung-Feng, et al.
Publicado: (2018)

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database
por: Tsai, Pei-Chien, et al.
Publicado: (2017)

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
por: Tsai, Yi-Shan, et al.
Publicado: (2020)

Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
por: Tsai, Yi-Shan, et al.
Publicado: (2022)

The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
por: Jang, Tyng-Yuan, et al.
Publicado: (2019)

The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
por: Batsaikhan, Batbold, et al.
Publicado: (2018)

Association of hyperuricemia with disease severity in chronic hepatitis C patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2018)

Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients
por: Huang, Chung-Feng, et al.
Publicado: (2013)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C: A Nationwide Survey in Taiwan
por: Yu, Ming-Lung, et al.
Publicado: (2015)

PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients
por: Huang, Chung-Feng, et al.
Publicado: (2015)

Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C
por: Yeh, Ming-Lun, et al.
Publicado: (2018)

Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication
por: Lu, Ming-Ying, et al.
Publicado: (2022)

Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance
por: Huang, Chung-Feng, et al.
Publicado: (2017)

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
por: Huang, Ching-I, et al.
Publicado: (2018)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2017)

Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
por: Jang, Tyng-Yuan, et al.
Publicado: (2021)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients
por: Yeh, Ming-Lun, et al.
Publicado: (2019)

Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan
por: Lu, Ming-Ying, et al.
Publicado: (2021)

Viral Interference Between Dengue Virus and Hepatitis C Virus Infections
por: Liang, Po-Cheng, et al.
Publicado: (2020)

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
por: Lin, Ching-Chih, et al.
Publicado: (2021)

Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients
por: Huang, Jee-Fu, et al.
Publicado: (2015)

Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients
por: Huang, Jee-Fu, et al.
Publicado: (2017)

Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan
por: Tsai, Pei-Chien, et al.
Publicado: (2021)

Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection
por: Liu, Hung-Yin, et al.
Publicado: (2021)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison
por: Chen, Chun-Ting, et al.
Publicado: (2022)

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
por: Yu, Ming-Lung, et al.
Publicado: (2005)

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy
por: Lin, Zu-Yau, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0majjgmslrsd83clbmlpacd17k